ClinicalTrials.gg
RecruitingNCT04218617Updated Nov 12, 2026

Single- vs. Two-Fraction Spine Stereotactic Radiosurgery for the Treatment of Vertebral Metastases

A Phase 2 interventional study of Diagnostic MRI and Planning MRI in Spine Metastases and Spine Stereotactic Radiosurgery (sSRS), sponsored by Case Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Case Comprehensive Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2020; still recruiting 6 years 9 months later.
Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Neoplasm Metastasis by Case Comprehensive Cancer Center — 1 open to participants now, 1 under way, none of them phase 3. Neoplasm Metastasis · Case Comprehensive Cancer Center.

Started
2020
with 1 other
Phase 2
6 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Neoplasm Metastasis by Case Comprehensive Cancer Center, this one is one of 2 that started in 2020, is one of 6 in phase 2, and was the 12th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

1 of the 12 studies in Neoplasm Metastasis by Case Comprehensive Cancer Center is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Neoplasm Metastasis by Case Comprehensive Cancer Center, or all of them as a file.
02

Study summary

Spine radiosurgery (SRS) utilizes advanced treatment planning with focused x-rays to deliver one to four high dose treatments to the spine to help relieve pain and/or neurologic symptoms. Spine SRS uses special equipment to position the participant and guide the focused beams toward the area to be treated and away from normal tissue.

One of the side effects of spine SRS is the development of vertebral compression fractures, many of which are not painful. The goal of this study is to compare the effects, good and/or bad, of spine SRS given in 1 or 2 treatments. Our main goal is to find out which approach will reduce the chances of developing vertebral compression fractures.

Read the detailed description

The primary objective of this study is to establish the non-inferiority in vertebral compression fracture (VCF) incidence at 6 months between single-fraction and two-fraction sSRS.

Other objectives are to to evaluate the 12-month impact of single- and two-fraction sSRS on local control (LC), pain control (PC), quality of life (QOL), and toxicity (specifically, pain flare, radiation esophagitis/laryngitis/pharyngitis, and radiation myelitis)

This study is planned as a two-arm randomized phase II trial to establish non-inferiority of single fraction sSRS compared to two-fraction sSRS. Approximately 130 participants will be enrolled in this trial; 65 participants in each arm:

  • Group 1: If you are assigned to this group, you will undergo spine radiosurgery in a single (1) session.
  • Group 2: If you are assigned to this group, you will undergo spine radiosurgery in two (2) sessions.
03

Conditions studied

  • Spine Metastases
  • Spine Stereotactic Radiosurgery (sSRS)

Browse trials for

Keywords

  • C79.40
  • C79.49
  • C79.51
  • C79.52
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Performance Status (KPS) ≥ 70
  • RPA class 1 (KPS >70 AND controlled systemic disease) or RPA Class 2 (KPS >70, uncontrolled systemic disease OR KPS ≤70, age ≥54, no visceral )44 (see Appendix II)
  • Vertebral metastases from C3 to L5 based on bone scan, CT, PET, or MRI.
  • Vertebral metastases must be (1) solitary, (2) at two contiguous levels, or (3) a maximum of three separate sites, with a maximum of two contiguous levels.
  • Radioresistant metastases are permitted (including sarcomas, melanomas, and renal cell carcinomas).
  • Patients with epidural disease are permitted so long as there is no cord compression.
  • Paraspinal extension is permitted, so long as the paraspinal component is ≤5 cm
  • Multiple small metastatic lesions (\<20% vertebral body involvement) of no clinical correlate are permitted, and not included in the irradiated segments as per RTOG 0631
  • History and physical within four weeks of registration.
  • Negative pregnancy test within four weeks of registration for women of .
  • Diagnostic spine MRI with and without contrast within four weeks of registration
  • Neurological exam within four weeks of registration to rule out rapid neurological decline. Mild to moderate neurological deficits are acceptable, as long as distance between lesion and spinal cord is ≥3 mm
  • Patients may have prior EBRT at the index site.
  • of the participant.

Exclusion criteria

Exclusion Criteria:

  • Lesions at C1-2 or S1-Coccyx.
  • Hematologic including lymphoma and myeloma.
  • Multiple primary cancers.
  • Primary neoplasms of the spine
  • Prior corpectomy, kyphoplasty/vertebroplasty, or instrumentation at the site of planned sSRS.
  • Spinal cord compression.
  • Paraspinal mass >5 cm.
  • Patients with rapid neurologic decline.
  • Bony retropulsion resulting in neurologic deficit.
  • Patients with to MRI.
  • Patients allergic to intravenous contrast for MRI or CT.
  • Patients with emergent spinal cord compression.
  • Patients with mechanical instability of the spine.
  • Patients with active connective tissue disease.
  • Patients who previously underwent sSRS to the vertebrae of interest.
  • Patients with diffuse or multilevel spinal disease with >20% involvement of vertebral bodies, defined as involvement of >5 vertebral levels.
  • Inability to participate in study activities due to physical or mental limitations.
  • Inability or unwillingness to return for all required follow-up visits and imaging.
  • Inability to deliver sSRS, either 18 Gy in one fraction, or 24 Gy in two fractions.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Arm 1 - Single fraction

    sSRS 18 Gy in 1 fraction

    Device: Diagnostic MRI · Device: Planning MRI · Other: Simulation CT · Other: QOL assessment · Other: Brief pain inventory (BPI) · Radiation: sSRS in 1 fraction

  • Active comparator
    Arm 2 - Two fraction

    sSRS 24 Gy in 2 fractions

    Device: Diagnostic MRI · Device: Planning MRI · Other: Simulation CT · Other: QOL assessment · Other: Brief pain inventory (BPI) · Radiation: sSRS in 2 fraction

Interventions

  • DeviceDiagnostic MRI

    Diagnostic MRI

  • DevicePlanning MRI

    Planning MRI: high definition (HD) MRI of the region of interest (1 vertebral level above and below the level(s) being treated)

  • OtherSimulation CT

    Simulation CT is obtained (1.5 mm slice thickness)

  • OtherQOL assessment

    QOL assessment

  • OtherBrief pain inventory (BPI)

    Brief pain inventory (BPI), including narcotic assessment

  • RadiationsSRS in 1 fraction

    sSRS 18 Gy in 1 fraction

  • RadiationsSRS in 2 fraction

    sSRS 24 Gy in 2 fractions to be delivered either on consecutive days or one day apart.

06

What researchers measure

Primary outcomes

  1. 6-month cumulative incidence of Vertebral Compression Fracture (VCF) associated with single- and two-fraction sSRS

    6-month cumulative incidence of Vertebral Compression Fracture (VCF) associated with single- and two-fraction sSRS Each treated vertebra will be assessed individually for VCF during radiologic follow-up

    Time frame: At baseline and for each subsequent follow-up MRI (at 1 month, 3 months, 6 months and 12 months after treatment)

Secondary outcomes

  1. Local control (LC) as defined as absence of local progression of disease In the event of disease progression, all cases will be reviewed at the multi-disciplinary spine tumor board for a consensus recommendation

    LC as defined as absence of local progression of disease, which include the following: 1. Gross unequivocal increase in tumor volume or linear dimension. 2. Any new or progressive tumor within the epidural space. 3. Neurologic deterioration attributable to pre-existing epidural disease with equivocal increased epidural disease dimensions on MRI.

    Time frame: At baseline and for each subsequent follow-up MRI (at 1 month, 3 months, 6 months and 12 months after treatment)

  2. Pain control (PC) as assessed by the Brief Pain Inventory (BPI)

    PC at each treated vertebral level assessed by the BPI \[9 item questionnaire (range: 0-10), higher scores = worse pain\], then defined by RTOG 0631 as follows: Complete relief (CR): Pain score of 0 at index site 3 mo post-treatment. CR is requisite of no increase in narcotic analgesics. Partial relief (PR): Reduction in BPI of ≥ 3 points at index site, provided other treated lesions have increased in pain score and participant did not require increase in narcotic analgesics for site of interest. Participants needing increase in narcotics for site will not be scored as having PR. Those needing increase in narcotics for a distant site will remain eligible for CR/PR. Stable response (SR): Post-treatment pain score same as or within 2 points of baseline score at index site with no increase in narcotic analgesics for site of interest. Progressive pain: Post-treatment increase of at least 3 points from baseline pain score at index site or increase in narcotics for site of interest.

    Time frame: At baseline and for each subsequent follow-up MRI (at 1 month, 3 months, 6 months and 12 months after treatment)

  3. Quality of life (QOL) assessed by EORTC QLQ-C30 (with BM22)

    Quality of life as measured by (EORTC QOL-C30) - 30 items that are grouped into five scales functional (physical, social, emotional functioning, cognitive and role), three scales of symptoms (fatigue, pain, nausea and vomiting), a global scale of health / quality of life and a number of related individual items with the symptoms of the disease and its treatment, as well as an item of economic impact. The answers to the items on the scales refer to "last week," except the patient's physical functioning scale whose time frame is the present. These answers obey a Likert format, which ranges from 1 ("Not at all") and 4 ("A lot")

    Time frame: At baseline and for each subsequent follow-up MRI (at 1 month, 3 months, 6 months and 12 months after treatment)

  4. Toxicity as assessed by CTCAE V. 5.0

    Toxicity as assessed by criteria in the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Rates of grade 1-5 toxicities will be reported

    Time frame: At follow-up MRI (1 month, 3 months, 6 months and 12 months after treatment)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie results in publication, after de-identification

Time frame: 1 year after last participant is enrolled. Data will be available for a total of 2 years

Access criteria: Investigators whose purposed use of the data has been approved by the Cleveland Clinic Independent Review Committee. Data will be provided for individual participant meta-analysis. All requests must be made in writing to Sam Chao, MD (Chaos@ccf.org) or Ehsan Balagamwala (Balagae@ccf.org).

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Jan 2027, 83 months after the start.

Of 354 non-industry phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 90. This study's planned 83 months is above that.

Counting every sponsor, half of 442 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Oct 2026 → Jan 2027 and completion Oct 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2020
First posted
Jan 6, 2020
StartActual
Feb 7, 2020
Primary completionEst.
Jan 2027was Oct 2026
CompletionEst.
Jan 2027was Oct 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Jan 2027
Nov 12, 2026
Study completion
Oct 2026→Jan 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Oct 2026→Jan 2027
    Study completion Oct 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04218617
Responsible party
Sponsor
First posted
Jan 6, 2020
Start date
Feb 7, 2020
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Samuel T Chao, MD
Contact
TaussigResearch@ccf.org
1-866-223-8100
Ehsan Balagamwala, MD
Contact
balagae@ccf.org
1-866-223-8100
Samuel Chao, MD
principal investigator · Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion